Coverage of the continuous glucose monitor for people with type 1 and insulin-requiring type 2 diabetes goes into effect on July 1, 2023. UnitedHealthcare, the largest health insurance company in the U.S., covers more than 45 million lives. Its offerings include health benefits, affordable coverage, a simplified healthcare experience and access to high-quality care.
Germantown, Maryland-based Senseonics designed its next-generation Eversense E3 CGM for long-term monitoring. The 180-day implantable CGM received FDA approval in February of last year.
Eversense E3 features a fully implantable third-generation sensor with sacrificial boronic acid (SBA) technology. The enhanced sensor longevity makes it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.
Senseonics said the latest coverage adds to the existing payers who include Eversense in their CGM coverage policies. These policies now benefit approximately 300 million covered lives, enabling Senseonics’ global commercial partner Ascensia Diabetes Care to reach more people.
“The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes. With the addition of UnitedHealthcare, we are nearing all insured adults in the United States having access to the Eversense E3 CGM System,” said Tim Goodnow, president and CEO of Senseonics. “The Eversense E3 CGM system enables patients and health care providers to effectively manage diabetes for six months with sustained accuracy and a removable smart transmitter that provides vibratory alerts and comprehensive data regarding glucose values and trends.
“We are excited about the expanded opportunity to provide these differentiated benefits of Eversense to more people with diabetes in collaboration with our global commercial partner Ascensia Diabetes Care.”
